➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
McKesson
Boehringer Ingelheim
Colorcon

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,028,912


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,028,912
Title:Method of lyophilizing liposomes
Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
Inventor(s): Cabral-Lilly; Donna (Pennington, NJ), Mayer; Lawrence (North Vancouver, CA), Tardi; Paul (Surrey, CA), Watkins; David (East Greenwich, RI), Zeng; Yi (Somerset, NJ)
Assignee: CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:14/352,662
Patent Claims: 1. A lyophilized gel-phase liposomal composition, wherein said gel-phase liposomes exhibit a melting phase temperature (T.sub.c) of at least 37.degree. C. and the liposome membrane is comprised of distearyl phosphatidyl choline (DSPC):distearyl phosphatidyl glycerol (DSPG):cholesterol at a molar ratio of 7:2:1; and said liposomes are stably associated with daunorubicin:cytarabine at a molar ratio of 1:5; and contain less than 50 mM internal cryoprotectant; and wherein a cryoprotectant that consists of one or more saccharides is present external to said liposomes; and wherein when said gel-phase liposomal composition is reconstituted, the mean diameter of the liposomes increases by no more than 25% as compared to said value measured prior to lyophilization and at least 90% of each agent is retained.

2. The composition of claim 1 wherein the ratio of daunorubicin:cytarabine changes by no more than 25% as compared to said composition prior to lyophilization.

3. The composition of claim 1 wherein the mean diameter of the liposomes increases by no more than 15% after lyophilization and upon reconstitution of said liposomes as compared to said value measured prior to lyophilization.

4. The composition of claim 3 wherein the mean diameter of the liposomes increases by no more than 10% after lyophilization and upon reconstitution of said liposomes as compared to said value measured prior to lyophilization.

5. The composition of claim 1 wherein the size distribution of the liposomes changes by no more than 25% after lyophilization and upon reconstitution of said liposomes.

6. The composition of claim 5 wherein the size distribution of the liposomes changes by no more than 15% after lyophilization and upon reconstitution of said liposomes.

7. The composition of claim 6 wherein the size distribution of the liposomes changes by no more than 10% after lyophilization and upon reconstitution of said liposomes.

8. A method to prepare the composition of claim 1 which method comprises subjecting to lyophilization an aqueous medium comprising gel-phase liposomes that exhibit a melting phase temperature (T.sub.c) of at least 37.degree. C. and the liposome membrane is comprised of distearyl phosphatidyl choline (DSPC):distearyl phosphatidyl glycerol (DSPG):cholesterol at a molar ratio of 7:2:1 and said liposomes are stably associated with daunorubicin:cytarabine at a molar ratio of 1:5 and contain less than 50 mM internal cryoprotectant, in the presence of external protectant that consists of one or more saccharides.

9. The method of claim 8 wherein said medium comprising gel-phase liposomes is frozen at a temperature which is below the glass transition temperature (T.sub.g) of said medium.

10. A method to prepare a pharmaceutical composition for administering therapeutic and/or diagnostic agents to a subject which method comprises reconstituting the liposomal composition of claim 1 in a pharmaceutical carrier to obtain a reconstituted composition.

11. A method to administer therapeutic and/or diagnostic agents to an animal subject which method comprises administering to said subject the reconstituted composition of claim 10.

12. The method of claim 11 wherein said administering is parenteral.

13. The method of claim 11 wherein the subject is human.

14. The composition of claim 1 wherein said mean diameter is maintained for at least 6 months upon storage at 5.degree. C. or at 25.degree. C.

15. The composition of claim 1 wherein said retaining is maintained for at least 6 months upon storage at 5.degree. C. or at 25.degree. C.

16. The composition of claim 1 wherein said cryoprotectant external to said liposomes comprises sucrose.

17. The composition of claim 1 wherein the external medium contains 250 mM-400 mM cryoprotectant.

18. The composition of claim 17 wherein the medium contains about 300 mM cryoprotectant.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
Mallinckrodt
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.